iShares Genomics Immnlgy & Hlthcr ETF (IDNA)
22.73
+0.08
(+0.35%)
USD |
NYSEARCA |
Mar 24, 16:00
22.73
0.00 (0.00%)
After-Hours: 17:32
Key Stats
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.47% | 0.03% | 144.09M | 25524.00 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.60% | 59.00% | -18.54M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| NYSE FactSet Glb Gnmcs&Imm Bio NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 3.72 yrs |
| Jennifer Hsui | 3.72 yrs |
| Paul Whitehead | 1.16 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
48
-18.54M
-2.719B
Category Low
6.230B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 23, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 23, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| BeiGene Ltd Ordinary Shares | 5.65% | -- | -- |
| Takeda Pharmaceutical Co Ltd | 5.43% | 32.74 | -0.46% |
| Sanofi SA | 5.30% | 105.00 | 0.89% |
| Exelixis Inc | 5.24% | 18.49 | 0.87% |
| Regeneron Pharmaceuticals Inc | 4.86% | 820.34 | 2.27% |
| Blueprint Medicines Corp | 4.56% | 43.46 | -0.34% |
| Roche Holding AG | 4.26% | 285.03 | 2.01% |
| Moderna Inc | 4.09% | 150.84 | 0.95% |
| Vir Biotechnology Inc | 3.99% | 22.49 | 1.03% |
| Genmab A/S | 3.91% | 370.90 | -0.13% |
News
Headline
Wire
Time (ET)
SA Breaking News
01/03 08:07
Basic Info
| Investment Strategy | |
| The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| NYSE FactSet Glb Gnmcs&Imm Bio NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 3.72 yrs |
| Jennifer Hsui | 3.72 yrs |
| Paul Whitehead | 1.16 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-24-23) | 0.60% |
| 30-Day SEC Yield (2-28-23) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 21, 2023
Fund Details
| Key Dates | |
| Inception Date | 6/11/2019 |
| Last Annual Report Date | 7/31/2022 |
| Last Prospectus Date | 12/1/2022 |
| Attributes | |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
SA Breaking News
01/03 08:07